Sialic Acid-Binding Immunoglobulin-Like Lectin 9 as a Potential Therapeutic Target for Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a silent but deadly global health crisis. It’s the third leading cause of death worldwide, affecting over 328 million people—more than the population of the United States. For patients, COPD means progressive breathing difficulty, chronic bronchitis, and emphysema (permanent lung damage). Even worse, current treatments like bronchodilators and steroids only ease symptoms, not the underlying inflammation that drives the disease.
But there’s hope: a protein called Siglec-9 (sialic acid-binding immunoglobulin-like lectin 9) is emerging as a game-changer for treating COPD. Here’s why it matters—and how it could transform care for millions.
The Root of COPD: Overactive Neutrophils
To understand Siglec-9’s promise, we first need to look at the neutrophil problem in COPD. Neutrophils are the body’s frontline immune cells—they rush to infection sites to kill bacteria and then die off, limiting damage. But in COPD, this system breaks down.
Cigarette smoke, air pollution, or repeated infections (like from Haemophilus influenzae) trigger two deadly changes:
- Neutrophils live too long: Pro-inflammatory signals (e.g., GM-CSF, IL-8) keep neutrophils alive far beyond their normal 1–2-day lifespan.
- Neutrophils cause collateral damage: Instead of dying, they release toxic molecules—like elastase (destroys lung tissue), ROS (free radicals), and NETs (sticky DNA webs)—that erode airways and alveoli (the tiny air sacs in lungs).
The result? Chronic inflammation, mucus buildup, and irreversible lung damage. Worse, standard steroids—great for asthma’s eosinophilic inflammation—do nothing for COPD’s neutrophilic fire.
Enter Siglec-9: A Brake on Overactive Neutrophils
Siglec-9 is a protein found almost exclusively on neutrophils and monocytes (another immune cell). Its job? Act as a “brake” on overactive immune responses. Here’s how:
1. It Triggers Neutrophil Death (In a Good Way)
When Siglec-9 binds to its ligands (molecules that fit like a key in a lock), it activates apoptosis (programmed cell death)—the natural way neutrophils “turn off” after fighting infection. In pro-inflammatory environments (like COPD lungs), Siglec-9 even switches to autophagic cell death—a more potent way to clear damaged cells.
This is huge for COPD: If we can “flip the switch” on Siglec-9, we could shrink the army of overactive neutrophils causing lung damage.
2. It Stops Neutrophil Recruitment
Neutrophils don’t just live too long—they’re over-recruited to COPD lungs. Siglec-9 puts the brakes on this by:
- Blocking signals (like CD11b integrin) that let neutrophils stick to blood vessels and enter airways.
- Suppressing pro-inflammatory cytokines (like TNF-α) that call more neutrophils to the fight.
In mice, the functional “twin” of Siglec-9—Siglec-E—does the same thing: Mice without Siglec-E have worse lung inflammation, while activating Siglec-E cuts neutrophil buildup by half.
Why Siglec-9 Is Different from Current Treatments
Current COPD therapies are like putting a bandage on a bullet wound—they treat symptoms but not the cause. Siglec-9 is different because it:
- Targets the root cause: Neutrophilic inflammation, the driver of COPD progression.
- Is cell-specific: It acts only on neutrophils/monocytes, so it won’t suppress the entire immune system (a major flaw of steroids).
- Has preclinical proof: Mouse studies show Siglec-E activation reduces lung damage. Human studies link Siglec-9 levels to COPD severity—higher Siglec-9 means fewer exacerbations.
The Catch: Natural Ligands and Genetic Variants
Like any new target, Siglec-9 has hurdles:
- We don’t fully know its natural ligands: Molecules that bind Siglec-9 (e.g., sialylated proteins, hyaluronan) are still being identified. Some bacteria (like Group B Streptococcus) even hijack Siglec-9 to suppress immune responses—we need to turn that against COPD.
- Genetic variants matter: Two common SIGLEC9 gene mutations (rs2075803, rs2258983) make Siglec-9 less effective. Patients with these variants have more severe emphysema and frequent exacerbations.
The Future: Siglec-9 as a COPD Therapy
Researchers are already exploring ways to harness Siglec-9:
- Agonist drugs: Molecules that bind Siglec-9 to trigger neutrophil death.
- Soluble Siglec-9: A lab-made version that blocks harmful ligands (e.g., bacterial sialic acids) from hijacking the protein.
- IVIg therapy: Intravenous immunoglobulin (IVIg) contains natural anti-Siglec-9 antibodies—early studies show it reduces neutrophil activity in inflammatory diseases.
For COPD patients, this could mean more than just breathing easier—it could slow or stop disease progression.
Conclusion
COPD has long been a “silent killer” because we lacked tools to target its root cause. Siglec-9 changes that. By controlling overactive neutrophils, it offers a path to treatments that don’t just relieve symptoms but heal lungs.
The road ahead involves decoding Siglec-9’s ligands, testing agonists in clinical trials, and personalizing therapy for genetic variants. But for the first time in decades, there’s real hope for a disease that has devastated millions.
This study was published by Zi Chen, Linfu Zhou, and colleagues from Nanjing Medical University and Brown University in the Chinese Medical Journal (2021).
doi.org/10.1097/CM9.0000000000001381
Was this helpful?
0 / 0